Oridonin induces Mdm2-p60 to promote p53-mediated apoptosis and cell cycle arrest in neuroblastoma

Han-Qing Zhu1 | Chao Zhang2 | Zhu-Ying Guo1 | Jun-Mei Yang3 | Jia-Hui Guo1 | Chen Chen1 | Qiang-Hua Yao4 | Feng Liu1 | Quan-Wu Zhang5 | Feng-Hou Gao1

Abstract
Oridonin could induce NB (neuroblastoma) cells growth inhibition by inducing apoptosis and cell cycle arrest, and the molecular mechanisms behind the effects deserve to be further explored. Here, oridonin was confirmed to cause the reactivation of p53 (cellular tumor antigen p53) to promote the expression of a series of apoptosis- and cell cycle arrest-related proteins for the biological effects. During the process, oridonin relied on the caspase activation to cleave p53-induced Mdm2 (E3 ubiquitin-protein ligase Mdm2) to generate Mdm2-p60. The generation of Mdm2-p60 stabilized p53, and resulted in p53 accumulation for p53 continuous activation. In our research, it was also found that the reactivation of p53 induced by oridonin was closely related with the generation of ROS (reactive oxygen species). Taken together, these findings explain that oridonin exerts its anticancer activity partially by targeting the Mdm2-p53 axis in NB cells, which lay an experimental base for future research of exploring the effects and molecular mechanisms of oridonin.

KEYWORDS
apoptosis, cell cycle arrest, Mdm2-p60, Oridonin, p53, ROS
1 | INTRODUCTION

NB (neuroblastoma), which originates from the neural crest, is the malignant solid tumor of great heterogeneity in children and babies, whose age of onset is commonly from 1 to 5 years old.\(^1\) Although great progress has been made in the surgery, chemotherapy, and radiation therapy for NB over the past 20 years, the treatment of the elderly and end-stage patient whose 5-year survival rate is less than 30% is still a tough problem to be solved.\(^1\) Chemotherapy is preferred because of the difficulty of executing surgery and radiation therapy for the advanced patients. To provide new hope for the chemotherapy of NB, it is necessary to find effective targets molecules in NB and seek candidate compounds or their derivatives which target these molecules.

Cell apoptosis inhibition and cell cycle checkpoint runaway are the hallmarks of tumor development and progression, and are significant features of cancer.\(^2\) The tumor suppressor p53 usually functions as a transcription factor. The activation of p53 induced by external stimulation can suppress the proliferation of cancer cells, because it can promote the expression of a series of related proteins to induce cell apoptosis and cell cycle arrest.\(^3,4\) However, the inactivation or low expression of p53 and mutations of \(TP53\) (tumor protein p53) frequently occur in human cancers of different types.\(^5,6\) In NB, \(TP53\) rarely mutates and the signaling pathways on the downstream of p53 are intact.\(^7\) Meanwhile, p53 inactivation is considered to be the most frequent mechanism of the drug resistance in NB cells.\(^8\) Furthermore, it has already been confirmed that reactivation of p53 in NB cells can induce cell apoptosis through the signaling pathways on the downstream of p53.\(^9,10\) Based on these findings, exploring small molecular compounds which can reactivate p53 to induce NB cells apoptosis and cell cycle arrest may provide a promising solution for the treatment of NB.\(^9,11,12\)

Oridonin is a kind of active diterpenoid derived from traditional Chinese medicine.\(^13\) It has a wide range of biological effects, such as anticancer, antibacterial, and anti-inflammatory activities.\(^14\) And, many oridonin derivatives have been designed and synthesized.\(^14,15\) Oridonin has strong anticancer activity that can extend the survival period of models of transplanted human esophageal and gastric tumor in mice.\(^16\) As reported in the literature, oridonin can induce apoptosis or cell cycle arrest in pancreatic cancer, gastric cancer, liver cancer, prostate cancer, and colorectal cancer cells.\(^17,20\) It is especially crucial that several studies have shown that during the apoptosis of cancer cells induced by oridonin or its derivatives, p53 is reactivated and the proteins on the downstream of p53 are also altered.\(^20,21\) For example, oridonin induces the growth inhibition and apoptosis of gastric cancer cells by regulating the expression and function of p53,\(^22\) the anticancer effects of oridonin on colon cancer cells are mediated through BMP7/
#ZHUTEL.

SH-SY5Y cells were cultured in 45% F-12 (#C11765500BT, gibco, USA) plus 45% MEM (#SH30024.01, HyClone, USA) supplemented with 10% FBS, 10^5 units L\(^{-1}\) penicillin, 100 g L\(^{-1}\) streptomycin, and 2-mmol L\(^{-1}\) glutamine (#25030081, gibco, USA). SK-N-MC cells were cultured in MEM supplemented with 10% FBS, 10^5 units L\(^{-1}\) penicillin, 100 g L\(^{-1}\) streptomycin, and 2-mmol L\(^{-1}\) glutamine. SK-N-SH, 293T, HELA, MEF, and MEF Trp53−/− cells were cultured in DMEM (#SH30243.01, HyClone, USA) supplemented with 10% FBS, 10^5 units L\(^{-1}\) penicillin, and 100 g L\(^{-1}\) streptomycin. The cells were maintained in the incubator containing 5% CO\(_2\) at 37°C. 27

##2.3 Western blot

Cells (70%-80% cell confluent monolayer in the 6-cm cell culture dish) were washed with PBS buffer twice and were added with 300-μL SDS lysis buffer. The SDS lysis buffer was formulated as follows: 50-mmol L\(^{-1}\) Tris-HCl (pH6.8) (#ST768, Beyotime Biotech, China), 100-mmol L\(^{-1}\) DTT (#ST040, Beyotime Biotech, China), 2% SDS (sodium dodecyl sulfate) (#ST626, Beyotime Biotech, China), 10% glycerol (#G116202, Aladdin, China), and ddH\(_2\)O. The cell lysate was heated at 100°C for 5 minutes and then was placed on ice for 5 minutes for three times. After centrifuge at 12,000 g for 1 minute at room temperature, the supernatant of the cell lysate was collected by discarding the pellet. The protein concentration of the cell lysate was determined by the spectrophotometer (#NanoDrop 2000/2000c, Thermo Fisher Scientific, USA). Bromophenol blue (#B8120, Solarbio, China) was added to the cell lysate to the final concentration of 0.05%. The initial loading of the total protein per well was 100 μg, which was adjusted according to the results. The gel consisting of the 10% separation gel and the 5% stacking gel was used to separate proteins with the molecular weight of 30-120 kDa. The gel consisting of the 12% separation gel and the 5% stacking gel was used to separate proteins with the molecular weight of 10-30 kDa. Following that, the proteins of the cell lysate were separated via SDS-PAGE and then were transferred to the nitrocellulose membrane with pore size of 0.22 μm using the wet transfer method. The membrane containing the proteins was transferred to 5% skim milk buffer which was formulated by dissolving the nonfat powdered milk (#A600669, Sangon Biotech, China) in the TBST buffer. The blocking membrane was rocked on shaker for 1 hour at room temperature. And the membrane was further transferred to the buffer containing specific primary antibodies and was rocked on shaker at 4°C overnight. After that, the membrane was washed with the TBST buffer for 5 minutes for three times. Then the membrane was transferred to the buffer containing specific secondary antibodies and was rocked on shaker for 1 hour at room temperature. 28

Antibodies used were as follows: anti-cleaved caspase-3 (#9661, CST, USA, 1:1000, 17/19 kDa), anti-cleaved caspase-3 (#9664, CST, USA, 1:1000, 17/19 kDa), anti-Flag (#14793, CST, USA, 1:1000), anti-p53 (#2524, CST, USA, 1:1000, 53 kDa), anti-ubiquitin (#3933, CST, USA 1:1000), anti-cyclin-B1 (G2/mitotic-specific cyclin-B1) (#4138, CST, USA, 1:1000, 55 kDa), anti-phospho-histone H3 (Ser10) (#53348, CST, USA, 1:1000, 17 kDa), anti-cleaved PARP (poly [ADP-ribose] polymerase) (#5625, CST, USA, 1:1000, 89 kDa), anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (#5174, CST, USA, 1:5000, 37 kDa), anti-Mdm2 (#sc-812, Santa Cruz, USA, 1:250, 90 kDa), anti-Mdm2-p60 (#sc-5304, Santa Cruz, USA, 1:250, 60 kDa), anti-p53 (#sc-6243, Santa Cruz, USA, 1:1000, 53 kDa), anti-BAX (apoptosis regulator BAX) (#sc-7480, Santa Cruz, USA, 1:1000, 23 kDa), anti-CDKN1A (cyclin-dependent kinase inhibitor 1A) (#SAB4500655, Sigma, USA, 1:500, 21 kDa), HRP-conjugated rabbit anti-mouse antibody (#315-035-003, Jackson Immuno Research, USA, 1:5000), and HRP-conjugated goat anti-rabbit antibody (#111-035-003, Jackson Immuno Research, USA, 1:5000). The primary antibodies were diluted with the primary antibody dilution buffer (#P0023A, Beyotime Biotech, China). The secondary antibodies were diluted with the 5% skim milk buffer. The membrane was washed again according to the above condition before imaging. ECL reagent (#WBKLS0500, Millipore, USA) was prepared according to the instruction and was added to the membrane. The digital imager (#FUSION FX7, Vilber-Lourmat, France) with the automatic mode was used for detection. With the GAPDH protein band as a loading control, the gray value of the protein brand was quantitatively analyzed by ImageJ (version k 1.45) software. All experiments were performed three times independently with similar results.

##2.4 Immunoprecipitation

Cells (70%-80% cell confluent monolayer in the 6-cm cell culture dish) were washed with PBS buffer twice and were added with 300-μL RIPA lysis buffer (#P0013D, Beyotime Biotech, China) containing inhibitors of protease and phosphatase (#4693132001, #490683700, Roche, Switzerland). Then the cell lysate was placed on ice for 30 minutes, and was vibrated every 10 minutes. Following that, the cell lysate was treated by the ultrasonic cell disruptor (power: 200 W; mode: work 4 seconds, stop 3 seconds, for five times) (#DH92-IIN, LAWSON, China). The supernatant of the cell lysate was collected and divided into two parts: one (250 μL) for the immunoprecipitation assay of the target protein, and the other (30 μL) for the total protein analysis. The protocol for the immunoprecipitation assay was as follows: Two copies of ProteinA + G Agarose Beads (20 μL copy^{-1}) (#P2012, Beyotime Biotech, China) were taken for each sample of cell lysate, one for the preincubation...
of the sample and the other for the preincubation of the antibody. Each copy of ProteinA+G Agarose Beads was washed with RIPA lysis buffer. The sample preincubation: the sample was added with one copy of the washed beads and was inverted at 4°C for 1 hour; the supernatant was collected after centrifuge at 2000g for 2 minutes at 4°C. The antibody preincubation: antibody was diluted with the 1-mL RIPA lysis buffer and was added with another copy of the washed beads, and then was inverted at 4°C for 4 hours; the supernatant was discarded to obtain the beads precipitate after centrifuge at 2000g for 2 minutes at 4°C. Antibodies used were as follows: anti-p53 (#2524, CST, USA, 1:200) and anti-IgG (#5415, CST, USA). The pretreated sample and the pretreated antibody binding to the precipitated beads were mixed and inverted at 4°C overnight. Following that, the beads were washed with RIPA lysis buffer five times and the protein binding to the beads was eluted by 30-μL SDS lysis buffer. After that, the Western Blot protocol was performed. All experiments were performed three times independently with similar results.

2.5 | Reverse transcription quantitative polymerase chain reaction

Total cellular RNA was extracted from cells using RNAsiso Plus reagent (#9109, TaKaRa, Japan) according to the instruction. Reverse transcription PCR was carried out by the PrimeScript RT reagent Kit (#RR047A, TaKaRa, Japan) in a volume of 10 μL for each sample, including 500 ng of total RNA without genomic DNA, 0.5-μL PrimeScript RT Enzyme Mix, 2-μL RT Primer Mix, 2-μL 5× PrimeScript Buffer, and RNase Free ddH₂O. The RT Primer Mix of the Kit contains Oligo dT Primer and Random 6 mers. The reaction mixture was initially heated at 37°C for 30 minutes, 85°C for 5 seconds, and finally at 4°C for 5 minutes to get the cDNA. For the quantitative PCR, PCR products were amplified from cDNA using the specific primers and 2× SYBR Premix Ex Taq II (Tli RNaseH Plus) Kit (#RR820A, TaKaRa, Japan) in the PCR machine (#LightCycler480, Roche, Switzerland). Quantitative PCR was carried out in a volume of 10 μL for each sample, including 5-μL 2× SYBR Premix Ex Taq II (Tli RNaseH Plus), 0.4-μL forward primers (10 μmol L⁻¹), 0.4-μL reverse primers (10 μmol L⁻¹), 1-μL cDNA (<100 ng), and 3.2-μL RNase Free ddH₂O. The condition of the two-step reaction was as follows: pre-denaturation at 95°C for 30 seconds, denaturation at 95°C for 5 seconds (40 cycles), and annealing/extension at 60°C for 30 seconds. The dissociation curve of each amplification reaction was checked to confirm that there was no nonspecific PCR product. The Ct values of Trp53 (transformation related protein 53), Actb (actin, beta), TP53, MDM2 (MDM2 proto-oncogene), and ACTB (actin beta) were normally 19-22, 14-16, 20-23, 20-23, and 14-17, respectively. Relative levels of Trp53, TP53, and MDM2 mRNA were determined by the 2⁻△△CT method using Actb or ACTB as the endogenous control. Primers (Sangon Biotech, China) were synthesized as follows: All experiments were performed three times independently with similar results.

| Target gene | Primer | Nucleotide sequence |
|-------------|--------|---------------------|
| Trp53 (Mouse) | F | 5'-TCACAGCGTCTGTTGACATT-3' |
| | R | 5'-ACCAAAGCTATTACCGTACA-3' |
| Actb (Mouse) | F | 5'-CTACCTCATGAAGATCTGGACC-3' |
| | R | 5'-CAACGGCTCTCTTGTAGTCA-3' |
| TP53 (Human) | F | 5'-CAGCACAATGACGAGGTTGTT-3' |
| | R | 5'-TCATCCAAAATACTCCACACGC-3' |
| MDM2 (Human) | F | 5'-AGCTTGAAGCAGTGGTGGACG-3' |
| | R | 5'-ACGATCACATTACAGGCAGGCT-3' |
| ACTB (Human) | F | 5'-ATAGCAGCAGCTCTGATGACAC GTAC-3' |
| | R | 5'-CACCTTCTACAATGAGCTGCT GTG-3' |

2.6 | Plasmids construction and transfection

The pcDNA3.1-MDM2 plasmids (#V790-20, invitrogen) and the pSin4-EFialpha-IREs plasmids (Vector backbone same as #61062, addgene) were obtained from Dr Ying-Li Wu. The pcDNA3.1-MDM2 (gene ID: 4193) plasmids containing the coding sequence of Mdm2 can be constructed on the basis of pcDNA3.1 plasmids. The coding sequence of Mdm2-p60 was amplified by PCR using the pcDNA3.1-MDM2 plasmids as the template, and the PrimeSTAR GXL DNA Polymerase Kit was used (#R050Q, TaKaRa, Japan). The primers for the PCR were as follows: F: 5'-GGGCTAGCTAGCTAGGAATTCATGGACTACAAAGACGATGACGACAAGA-3'，R: 5'-GGGCTAGCTAGCTAGGAATTCATGGACTACAAAGACGATGACGACAAGA-3'。PCR products were amplified from the pcDNA3.1 plasmids as the template, and the PrimeSTAR GXL DNA Polymerase Kit was used (#R050Q, TaKaRa, Japan). The primers for the PCR were as follows: F: 5'-GGGCTAGCTAGCTAGGAATTCATGGACTACAAAGACGATGACGACAAGA-3'，R: 5'-GGGCTAGCTAGCTAGGAATTCATGGACTACAAAGACGATGACGACAAGA-3'。PCR products were detected by 1% agarose gel electrophoresis and were purified by the TaKaRa MiniBEST Agarose Gel DNA Extraction Kit Ver.4.0 (#9762, TaKaRa, Japan). The pSin plasmids were digested by the restriction enzymes BamH I (#1605, TaKaRa, Japan) and EcoR I (#1611,
TaKaRa, Japan). The reaction was carried out in a volume of 50 μL, including 1-μg pSIN plasmids, 1-μL BamH I, 1-μL EcoR I, 5-μL 10 × QuickCut Buffer, and RNase Free ddH<sub>2</sub>O. The reaction condition was as follows: digestion at 37°C for 30 minutes. The reaction was stopped by 0.8% agarose gel electrophoresis, and the linearized pSIN plasmids were detected and purified by the TaKaRa MiniBEST Agarose Gel DNA Extraction Kit Ver.4.0. The ligation reaction of PCR products and the linearized pSIN plasmids was catalyzed by the ClonExpress II One Step Cloning Kit (#C112-01, Vazyme, China) to obtain the recombinant plasmids coding Mdm2-p60. The reaction was carried out in a volume of 20 μL, including 160-ng linearized pSIN plasmids, 60-ng PCR products, 2-μL Exnase II, 4-μL 5 × CE II Buffer, and RNase Free ddH<sub>2</sub>O. The reaction condition was as follows: ligation at 37°C for 30 minutes and on ice for 5 minutes. The recombinant plasmids were amplified and verified by DNA sequencing (GENEWIZ, China).

Cells (50%-60% cell confluent monolayer in the one well of 6-well plate) were transfected with pSIN or pSIN-Flag3-MDM2-p60 plasmids by the Lipofectamine 3000 Transfection Kit (#L3000-015, Invitrogen, USA). The procedure was as follows: The Mix I solution consists of 6-μL Lipofectamine 3000 Reagent and 250-μL Opti-MEM Medium (#31985-062, gibco). The Mix II solution consists of 2-μg pSIN/pSIN-Flag3-MDM2-p60 plasmids, 4-μL P3000 Reagent, and 250-μL Opti-MEM Medium. The above I and II solutions were thoroughly mixed and placed at room temperature for 5 minutes. Then the mixture was added to one well of 6-well plate which contains 1.5-mL normal medium. The transfected cells were digested by 0.25% trypsin without EDTA, and the cell density was 5000 well−1. After the cells were attached to the wall, they were treated with 100-μL medium containing 5% CO<sub>2</sub> at 37°C for 1-4 hours. The OD (optical density) value of the control group without oridonin treatment should be controlled to 0.8-1.2, and that can make the results more reliable. The absorbance of each well was measured at 450 nm using a microplate reader (#Synergy2, BioTek, USA). Cell viability = (OD value<sub>the experimental group</sub>−Mean of the OD value<sub>the blank group</sub>)/(Mean of the OD value<sub>the control group</sub>−Mean of the OD value<sub>the blank group</sub>) × 100%. Cell inhibitory rate = 100%−Cell viability. All experiments were performed three times independently with similar results.

### 2.8 | Annexin V-FITC/PI staining

Cell apoptosis was evaluated by the Annexin V-FITC/PI Apoptosis Detection Kit (#40302ES20, YEASEN, China). Cells were digested by 0.25% trypsin without EDTA and were washed by PBS buffer twice. 1-5 × 10<sup>5</sup> cells were precipitated and suspended by 100-μL 1 × Binding Buffer. Cell suspension was mixed with 5-μL Annexin V-FITC plus 10-μL PI Staining Solution, and was placed at room temperature for 10-15 minutes out of light. Following that, cell suspension was further mixed with 400-μL 1 × Binding Buffer. Then the cell suspension should be placed on ice out of light and be detected by flow cytometry (#Epics XL, Beckman Coulter, USA) within 1 hour. All experiments were performed three times independently with similar results.

### 2.9 | PI staining

Cell cycle distribution was assessed by Cell Cycle and Apoptosis Analysis Kit (#C1052, Beyotime Biotech, China). Cells were digested by 0.25% trypsin without EDTA, and were washed by PBS buffer twice. Cell precipitation was re-suspended and fixed by 75% ice-cold ethanol at −20°C for 2 hours. Following that, cells were washed by PBS buffer twice and were re-suspended by 0.5-mL staining buffer. The cell density of the cell suspension was about 1 × 10<sup>6</sup> mL<sup>−1</sup>. The cell suspension was further mixed with 25-μL 20 × PI staining solution plus 10-μL 50 × RNase A, and was placed at room temperature for 30 minutes out of light. Then the cell suspension should be placed on ice out of light and be detected by flow cytometry within 24 hours. The FlowJo (version 7.6) software was used for cell cycle analysis. All experiments were performed three times independently with similar results.

### 2.10 | Murine model and oridonin treatment

A total of 36 BALB/c nude mice (age: 5 weeks; weight: about 22 g; sex: female) were purchased from Shanghai SLAC Laboratory Animal Company Limited (China), and were maintained in a specific pathogen-free environment. They were randomly assigned to six groups (six mice per group): four groups for xenograft model and two groups for pseudo metastatic model. Animal-related experiments were performed according to the Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, revised 1996) and were approved by the committee for human treatment of animals at Shanghai Jiao Tong University School of Medicine.
The xenograft models were established by subcutaneous injection of $2 \times 10^6$ NB41A3 cells in the right lower abdomen of the mice. When tumor became palpable, the nude mice were administered with drug (PBS, 10% DMSO, 10 or 20 mg kg$^{-1}$ oridonin) everyday by intraperitoneal injection. The longest diameter and its according perpendicular diameter of each tumor were measured everyday using caliper to estimate the tumor volume. The formula followed was used to calculate the volume of the tumor: $4\pi/3 \times (\text{width/2})^2 \times (\text{length/2})$. All the nude mice were sacrificed at the 28th day, and the tumors were collected for further experiments.

The pseudo-metastatic models were established by intravenous injection of $2 \times 10^5$ NB41A3 cells through the tail vein of the mice. After 3 days, the nude mice were administered with drug (0.2 mL PBS or 20 mg kg$^{-1}$ oridonin) every other day for 2 weeks by intraperitoneal injection. In the experiments, mice were monitored routinely for weight loss and were sacrificed when signs of poor health became evident. Survival time was used as the main criterion for determining treatment efficacy.

2.11 | Immunohistochemistry

Several sections with the thickness of 5 μm were cut from each paraffin-embedded tumor. Subsequently, these sections were immersed in xylene twice, 30 minutes each time. And, then they were transferred to graded ethanol. After that, they were completely rinsed by dH$_2$O. The sections were then placed in a high-pressure steamer containing 1 × Citrate Antigen Retrieval Solution (#P0081, Beyotime Biotech, China) to retrieve antigens by boiling for about 2 minutes. Endogenous peroxidase activity was blocked by immersing sections in 3% hydrogen peroxide-methanol buffer for 5 minutes. The sections were next blocked with 5% BSA-PBS buffer (#A600332, Sangon Biotech, China) for 40 minutes at room temperature to reduce nonspecific staining. Following that, the sections were transferred to the buffer containing specific primary antibodies at 4°C overnight. After the sections were sufficiently rinsed by PBS buffer, they were transferred to the buffer containing the HRP-conjugated secondary antibodies for 40 minutes at room temperature. The sections were stained for 5-10 minutes at room temperature out of light by the DAB Kit (#P0203, Beyotime Biotech, China). Finally, the sections were stained with hematoxylin and eosin. Antibodies used were as follows: anti-p53 (#sc-6243, Santa Cruz, USA, 1:100, 53 kDa), anti-CDKN1A (#SAB450065, Sigma, USA, 1:100, 21 kDa), HRP-conjugated rabbit antimouse antibody (#315-035-003, Jackson Immuno Research, USA, 1:1000), and HRP-conjugated goat anti-rabbit antibody (#111-035-003, Jackson Immuno Research, USA, 1:1000). The primary antibodies and secondary antibodies were diluted with 5% BSA-PBS buffer. The sections were observed and photographed by the inverted microscope (#ECLIPSE Ti-S, Nikon, Japan) using the NIS-Elements (BR 4.10.00) software under the 200x magnification. The ImageJ (version k 1.45) software was used for analysis.

2.12 | TUNEL

For preparing single-cell suspension, the technique described in a previous report was used. The cell density of the cell suspension was about $2 \times 10^7$ mL$^{-1}$. About 50-100 μL cell suspension was put onto each polylysine-coated section and was gently smeared with a clean section. Cells on sections were immersed in 4% poly-formaldehyde-PBS buffer at 4°C for 25 minutes to be fixed, and they were further incubated with 100-μL Proteinase K-PBS buffer (20 μg mL$^{-1}$) at room temperature for 40 minutes. Apoptosis of cells of different tumors was measured by TUNEL Apoptosis Detection Kit (Alexa Fluor 488) (#40307ES20, YEASEN, China). The sections were incubated with 100-μL 1 × Equilibration Buffer for 10-30 minutes at room temperature. After that, the 1 × Equilibration Buffer was absorbed by absorbent paper. Then the sections were incubated with 50-μL TdT Enzyme Buffer for 60 minutes at room temperature out of light. Following that, the sections were immersed in PBS buffer for 5 minutes at room temperature, and then were rinsed completely by PBS buffer. The sections were stained with 1 μg mL$^{-1}$ PI-PBS buffer for 5 minutes, and were also stained again with 2 μg mL$^{-1}$ DAPI-PBS buffer for 5 minutes. Both staining procedure should be at room temperature out of light. After that, the sections were rinsed completely by dH$_2$O. The percentage of apoptotic cells was determined by counting at least 1000 cells in 10 to 20 fields under the 200X magnification using phase-contrast and fluorescent microscopy.

2.13 | Statistical analysis

The measurement data are presented as the mean ± SD. The statistical analysis was performed using the software GraphPad Prism 5 or SPSS 22.0. A value of $P < 0.05$ was considered to be statistically significant. Nonparametric tests were used.

Statistical analysis of growth inhibition induced by oridonin on cancer cells, relative expression of mRNA, relative expression of protein, tumor volume, and tumor weight was analyzed with Kruskal-Wallis test and was presented as “$P$”, when Kruskal-Wallis test was significant it was followed by Dunn's multiple comparisons test and was presented as “$P_a$”. Statistical analysis of growth inhibition induced by oridonin on MEF and MEF Trp53$^{-/-}$ was analyzed using Mann-Whitney $U$ test and was presented as “$P_a$”. IC50 value was analyzed by GraphPad Prism 5. Statistical analysis of mice survival time was analyzed using Log-rank (Mantel-Cox) test and was presented as “$P$”.
3 | RESULTS

3.1 | Oridonin suppressed the proliferation of NB cells by inducing cell apoptosis and cell cycle arrest

We initially treated the NB41A3, SH-SY5Y, SK-N-SH, and SK-N-MC cells with a series of different concentrations of oridonin for 24 hours, and observed that oridonin could suppress the proliferation of NB cells (Figure 1A-D). To identify the mechanisms of the oridonin's inhibitory effects on NB cells, NB41A3 cells were treated with 20-μmol L⁻¹ oridonin for 12 and 24 hours. Then, cell necrosis and apoptosis were measured by Annexin V/PI staining using flow cytometry. The data proved that oridonin could induce NB41A3 cells apoptosis in the time-dependent manner (Figure 2A). For the detailed effects of oridonin on NB cells, NB41A3 cells were also treated with 10- or 20-μmol L⁻¹ oridonin for 24 hours. Cell cycle percentage detected by flow cytometry analysis showed that oridonin induced NB41A3 cells to be arrested in G2/M phase (Figure 2C). Furthermore, 20-μmol L⁻¹ oridonin also caused a significant increase in SubG1 phase (Figure 2C). Additionally, the oridonin-induced expression of cleaved caspase-3 and cleaved PARP in different NB cell lines further confirmed that oridonin could induce apoptosis (Figure 2B). After NB41A3 cells treated with 10-μmol L⁻¹ oridonin for 12 and 24 hours, the expression of cyclin-B1 and phospho-histone H3 (Ser10) was also enhanced (Figure 2D). These results indicated that oridonin may suppress the proliferation of NB cells by inducing cell apoptosis and cell cycle arrest.

FIGURE 1 Oridonin inhibited NB cells growth with different concentration. NB cell lines were treated with a series of different concentration of oridonin indicated for 24 hour. Cell viability was determined by the CCK-8 kit. The dots in the graphs represent independent experimental replicates. (A) NB41A3 cells were treated with 0, 1, 5, 10, 20, 40, and 80 μmol L⁻¹ oridonin. \( P_1 > 0.9999 \) (1 vs 0 μmol L⁻¹), \( P_2 > 0.9999 \) (5 vs 0 μmol L⁻¹), \( P_3 > 0.9999 \) (10 vs 0 μmol L⁻¹), \( P_4 = 0.5770 \) (20 vs 0 μmol L⁻¹), \( P_5 = 0.0710 \) (40 vs 0 μmol L⁻¹), and \( P_6 = 0.0240 \) (80 vs 0 μmol L⁻¹). (B) SH-SY5Y cells were treated with 0, 2, 4, 6, 8, 10, 15, and 20 μmol L⁻¹ oridonin. \( P_1 > 0.9999 \) (2 vs 0 μmol L⁻¹), \( P_2 > 0.9999 \) (4 vs 0 μmol L⁻¹), \( P_3 > 0.9999 \) (6 vs 0 μmol L⁻¹), \( P_4 > 0.9999 \) (8 vs 0 μmol L⁻¹), \( P_5 = 0.2620 \) (10 vs 0 μmol L⁻¹), \( P_6 = 0.0200 \) (15 vs 0 μmol L⁻¹), and \( P_7 = 0.0200 \) (20 vs 0 μmol L⁻¹). (C) SK-N-SH cells were treated with 0, 2, 4, 6, 8, 10, 15, and 20 μmol L⁻¹ oridonin. \( P_1 > 0.9999 \) (2 vs 0 μmol L⁻¹), \( P_2 > 0.9999 \) (4 vs 0 μmol L⁻¹), \( P_3 > 0.9999 \) (6 vs 0 μmol L⁻¹), \( P_4 > 0.9999 \) (8 vs 0 μmol L⁻¹), \( P_5 = 0.5850 \) (10 vs 0 μmol L⁻¹), \( P_6 = 0.1300 \) (15 vs 0 μmol L⁻¹), and \( P_7 = 0.0230 \) (20 vs 0 μmol L⁻¹). (D) SK-N-MC cells were treated with 0, 2, 4, 6, 8, 10, 15, and 20 μmol L⁻¹ oridonin. \( P_1 > 0.9999 \) (2 vs 0 μmol L⁻¹), \( P_2 > 0.9999 \) (4 vs 0 μmol L⁻¹), \( P_3 > 0.9999 \) (6 vs 0 μmol L⁻¹), \( P_4 > 0.9999 \) (8 vs 0 μmol L⁻¹), \( P_5 > 0.9999 \) (10 vs 0 μmol L⁻¹), \( P_6 = 0.2210 \) (15 vs 0 μmol L⁻¹), and \( P_7 = 0.0420 \) (20 vs 0 μmol L⁻¹).
Oridonin-induced p53 accumulation led NB cells apoptosis and cell cycle arrest

Based on the previous studies, we carried out research on p53. The MEF and MEF Trp53−/− cells were treated with 20-μmol L−1 oridonin for 0, 12, and 24 hour, respectively, and then cells were collected and apoptosis of cells was detected by flow cytometry. The difference of inhibitory effects suggested that p53 may play a role in the cell growth inhibition induced by oridonin (Figure 3B). We then detected the effects of oridonin on the expression of p53. As shown in the results, oridonin indeed increased the expression of p53 in the NB cell lines (Figure 3C). And, it was also found that the expression of CDKN1A and BAX was increased (Figure 3C), they are proteins regulated by p53 and are involved in the apoptosis and cell cycle arrest. These results were consistent with the previous theory that p53 accumulation can lead to cell cycle arrest and apoptosis by regulating the transcription of its target gene.30 To further validate p53’s role in the oridonin-induced apoptosis and cell cycle arrest, we pretreated NB41A3 cells with the p53 inhibitor PFT-α and observed that the upregulation of CDKN1A and BAX induced by oridonin was totally reversed by PFT-α (Figure 3D). These results indicated that oridonin can induce NB cells apoptosis and cell cycle arrest by reactivating p53 and regulating the proteins on the down-stream of p53.

Mdm2-p60 was generated in the apoptosis process to maintain p53’s continuous activation

There was no significant change in the mRNA level of TP53 when the NB cells were treated with oridonin (Figure 4A). Mdm2, which acts as the E3 ubiquitin ligase for p53, is considered to be the major negative regulator of p53,31 and the transcription of MDM2 also can be trans-activated by p53. Under oridonin treatment, the expression of Mdm2 was increased probably because MDM2’s transcription was enhanced by p53 (Figure S1A and B). Moreover, it could also be observed in all NB cell lines that oridonin induced the cleavage of Mdm2 and the generation of Mdm2-p60 (Figure 6B). Proteolytic cleavage of the Mdm2 was reported to depend on the activation of specific caspases.

Previous studies have proved that Mdm2-p60 failed to target p53 for degradation.32 Contrarily, Mdm2-p60 can bind to p53 to improve the p53’s stability. In support of
this view, when the induction of Mdm2-p60 was blocked by caspase inhibitor Z-VAD, the accumulation of p53 induced by oridonin was greatly decreased (Figure 4C). Taken together, these results indicated that oridonin-induced Mdm2-p60 can maintain the continuous activation of p53.
3.4 | Mdm2-p60 improved the p53’s stability by reducing its ubiquitination

Our results showed that oridonin may induce the accumulation of p53 by decreasing the ubiquitination of p53 (Figure 5A). We also discovered that Mdm2-p60 bound with p53, and p53’s ubiquitination reduction induced by Mdm2-p60 may result in the improvement of p53’s stability (Figure 5B and 5C). Furthermore, it was also demonstrated that the increased expression of Mdm2-p60 and p53 was also associated with ROS (Figure 5D).

3.5 | Oridonin inhibited the growth of NB xenograft with p53 and CDKN1A upregulation

The xenograft models were administered with drug (PBS, 10% DMSO, 10 or 20 mg kg⁻¹ oridonin) everyday by intraperitoneal injection for 28 days. Oridonin treatment resulted in the suppression of xenograft growth, compared with the DMSO treatment (Figure 6A). It was also observed that the treatment of oridonin could reduce the tumor weight, compared with the DMSO treatment (Figure 6B). The pseudo-metastatic models were established by intravenous injection of NB41A3 cells through the tail vein of the mice. After 3 days, the mice were administered with drug (0.2-mL PBS or 20 mg kg⁻¹ oridonin) every other day for 2 weeks by intraperitoneal injection. The results showed that oridonin treatment prolonged the lifespan of the pseudo-metastatic models, compared with the PBS treatment (Figure 6C). By H&E staining, sparse cancer cells and areas of necrosis can be seen in the tumor tissue of the oridonin treatment group, while massive cancer cells were observed in the tumor tissue of the PBS treatment group (Figure 6D). By immunohistochemistry, we found that the expression of p53 and CDKN1A was increased (Figure 6D).

To further confirm the effects of oridonin on cancer cells in vivo, single-cell suspension was derived from the tumor tissue of different groups. A large number of apoptotic cells could be observed in the oridonin treatment group by TUNEL assay (Figure 6E). Meanwhile, cell cycle percentage was analyzed by PI staining. The data indicated that both the low and high dose of oridonin induced tumor cells to be arrested in G2/M phase (Figure 6F).

4 | DISCUSSION

The low-level of p53 in NB cells is an important link in the development and progression of NB. Exploring methods to increase the expression of p53, which can cause cell cycle arrest and apoptosis, thereby playing a role in inhibiting NB cells growth, is a worthy research direction. In our research, we find that oridonin could induce Mdm2-p60 to promote p53-mediated apoptosis and cell cycle arrest in NB (Figure 7).

Oridonin was observed to inhibit cell growth and induce cell cycle arrest and apoptosis in NB cells. Since oridonin and its derivatives have been reported to be involved in the activation of p53-related pathways, we selected Trp53-deficient...
MEF and NB cells to observe the role of p53 in the oridonin’s effects. As expected, the different inhibition effects on MEF and MEF $Trp53^{−/−}$ cells, and the expression of p53 and the proteins on the downstream of p53, both proved that oridonin’s effects partially depended on p53. And, the rescue of oridonin‐induced CDKN1A and BAX by PFT‐α further confirmed p53’s role in the oridonin’s effects.

It was observed that the change of TP53 mRNA level was not the reason for the enhanced expression of p53 in NB cells. And, this finding is inconsistent with a previous report in gastric cancer cells.22 This may be due to the fact that cells of different origins respond differently to oridonin: gastric cancer cells originate from epithelial cells and NB cells originate from neural crest. Mdm2 is the major negative regulator of p53, for it can promote the degradation of p53 by increasing its ubiquitination. When NB cells were treated with oridonin, it was observed that Mdm2‐p60, which is a proteolytic cleavage product of Mdm2, was significantly increased. And the generation of Mdm2‐p60 was dependent on caspase‐3 activation. In fact, Mdm2 consists of 491 amino acids, and it contains a p53 Binding Domain at the N‐terminus and a Ring Domain which is essential for the E3 ubiquitin ligase activity

**FIGURE 6** Oridonin inhibited the growth of NB xenograft with p53 and CDKN1A upregulation. NB41A3 cells $(2 \times 10^6)$ were subcutaneously injected into nude mice. When tumors became palpable, the nude mice were administered with drug (PBS, 10% DMSO, 10 or 20 mg kg$^{−1}$ oridonin) everyday by intraperitoneal injection. (A) The sizes of tumor were monitored at the time indicated. The dots in the graphs represent independent biological replicates. $P_1 > 0.9999$ (10% DMSO vs PBS), $P_2 = 0.2470$ (10% DMSO vs 10 mg kg$^{−1}$), and $P_3 = 0.0030$ (10% DMSO vs 20 mg kg$^{−1}$). (B) The weights of tumor were monitored at the time indicated. The dots in the graphs represent independent biological replicates. $P_1 > 0.9999$ (10% DMSO vs PBS), $P_2 = 0.0960$ (10% DMSO vs 10 mg kg$^{−1}$), and $P_3 = 0.0220$ (10% DMSO vs 20 mg kg$^{−1}$). (C) The pseudo metastatic models were established by intravenous injection of NB41A3 cells through the tail vein of the mice. After 3 days, the mice were administered with 0.2 mL of PBS or oridonin (20 mg kg$^{−1}$) by intraperitoneal injection every other day for 2 weeks. (D) Expression of p53 and CDKN1A in tumor tissues of the indicated group by immunohistochemistry. (Bar = 100 μm) (E) Apoptosis of tumor cells of the indicated group by TUNEL assay. (Bar = 100 μm) (F) Cell cycle distribution of tumor cells of the indicated group by flow cytometry analysis.
at the C-terminus. Mdm2 can be cleaved by specific caspases to generate Mdm2-p60 which is a 60 kDa fragment containing 1-361 amino acids of Mdm2; moreover, the conserved sequence DVPD (358-361 amino acids) of Mdm2 is the caspase recognition site. Cooper GM et al firstly observed that in apoptotic cells, caspase-3 cleaved Mdm2 and Mdm2-p60 were generated. Chen J et al subsequently found that Mdm2-p60 existed in non-apoptotic cancer cells. Mdm2-p60 loses the Ring Domain so that it cannot target p53 to proteasome degradation, but with the remaining p53 Binding Domain it still can bind with p53. Tyler J et al proposed that after the DNA damage of cells, Mdm2-p60 maintained the p53’s stability by reducing the modifications of p53. During the oridonin-induced apoptosis of NB cells, we first discovered that the generated Mdm2-p60 maintained p53’s continuous activation by reducing p53’s ubiquitination (Figure 5C). Caspase-2 and caspase-3 are caspases currently reported to generate Mdm2-p60, and previous studies and our results showed that oridonin can activate caspase-3, which may participate in the oridonin-induced Mdm2’s cleavage. The transcription of full-length MDM2 with 10 coding exons can be regulated by both the P1 and P2 promoter. Meanwhile, p53 can upregulate MDM2 mRNA by inducing the MDM2’s transcription from the P2 promoter. This is probably the reason for the oridonin-induced upregulation of Mdm2. However, Mdm2 is considered to be the major negative regulator of p53. For it can bind to p53 to block p53-mediated transcriptional regulation, and also acts as an E3 ligase to promote the proteasome degradation of p53. According to this, Mdm2’s cleavage induced by caspases seems to be significant for p53’s continuous activation in oridonin-induced apoptosis and cell cycle arrest. Additionally, oridonin has been proved to be a small inhibitor of nucleolin, which participates in nucleolar stress associated with specific ribosomal proteins. Under nucleolar stress, ribosomal proteins-Mdm2-p53 pathway can result in p53 stabilization and activation, so it is well worthy to further explore whether oridonin reactivates p53 via regulation on nucleolin and related ribosomal proteins.

Consistent with previous studies in other cancers, oridonin induced NB cells apoptosis and cell cycle arrest by reactivating p53. Although it is worth noting that the reactivation of p53 is an important molecular mechanism of oridonin, our research showed that the effects of oridonin may not be completely dependent on P53. In MEF Trp53−/− cells, oridonin reduced cell’s viability by approximately 40% (Figure 3B). As well as in HELA cells where p53 is degraded due to the presence of HPV18 E6, oridonin treatment cannot induce significant increase in p53 but increase CDKN1A and BAX significantly (Figure S1D). Similarly, in TP53 null colon cancer cells, 5-FU (5-fluorouracil) can cause nucleolar stress to lead to cell cycle arrest and apoptosis. The nucleolar stress induced by 5-FU can further activate rpL3 (ribosomal protein L3), which induce the expression of its target gene CDKN1A and regulates it’s another target gene CBS (cystathionine-beta-synthase) to induce mitochondrial apoptosis characterized by an increase of BAX. This suggests that it is worth to explore whether oridonin can lead to cell cycle arrest and apoptosis via p53-independent pathways, such as inducing nucleolar stress to regulate ribosomal proteins like rpL3.

In summary, we identify the oridonin’s effects on NB cells and the molecular mechanisms of the effects. Oridonin induces apoptosis and cell cycle arrest of NB cells by reactivating p53.
Besides, the cleavage of Mdm2 promotes oridonin-induced p53-mediated cell apoptosis and cell cycle arrest. Moreover, there are several reports about oridonin's derivatives which are with higher activity. These data provide clues and directions for the exploration of oridonin’s derivatives, from which we hope to find more effective derivatives. Based on these efforts, we propose that oridonin exerts its antitumor activity partially by targeting the Mdm2-p53 axis in NB cells, and oridonin and its derivatives may be potential drugs for NB treatment.

ACKNOWLEDGMENTS

This work was supported in part by the National Natural Science Foundation of China (81572796, 81302006 and 81172322), Shanghai Municipal Education Committee (13ZZ089), Science and Technology Committee of Shanghai (14401901500), Science and Technology Committee of Baoshan District (12-E-2).

CONFLICTS OF INTEREST

The authors confirm that there are no conflicts of interest.

ORCID

Feng-Hou Gao https://orcid.org/0000-0001-5032-6955

REFERENCES

1. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397-411.
2. Li T, Kon N, Jiang L, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012;149:1269-1283.
3. Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harbor Perspect Med. 2016;6:a026104.
4. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9:402-412.
5. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumor regression in vivo. Nature. 2007;445:661-665.
6. Bykov V, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89-102.
7. Goldman SC, Chen CY, Lansing TJ, Gilmer TM, Kastan MB. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am J Pathol. 1996;148:1381-1385.
8. Tweddle DA, Pearson AD, Haber M, et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 2003;197:93-98.
9. Nicolai S, Pieraccioni M, Peschiarioli A, Melino G, Raschellà G. Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis. Cell Death Dis. 2015;6:e2010.
10. Kurata K, Yanagisawa R, Ohira M, Kitagawa M, Nakagawara A, Kamijo T. Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells. Oncogene. 2008;27:741-754.
11. Fan Y-H, Cheng J, Vasudevan SA, et al. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis. 2013;4:e867.
12. Cheng J, Fan Y-H, Xu X, et al. A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. Cell Death Dis. 2014;5:e1079.
13. Zhang LD, Liu Z, Liu H, et al. Oridonin enhances the anticancer activity of NVP-BEZ235 against neuroblastoma cells in vitro and in vivo through autophagy. Int J Oncol. 2016;49:657-665.
14. Xu J, Wold EA, Ding Y, Shen Q, Zhou J. Therapeutic potential of oridonin and its analogs: from anticancer and antiinflammation to neuroprotection. Molecules. 2018;23:474.
15. Ding Y, Ding C, Ye N, et al. Discovery and development of natural product oridonin-inspired anticancer agents. Eur J Med Chem. 2016;122:102-117.
16. Sun KW, Ma YY, Guan TP, et al. Oridonin induces apoptosis in gastric cancer through Apaf-1, cytochrome c and caspase-3 signaling pathway. World J Gastroenterol. 2012;18:7166-7174.
17. Gao F-H, Hu X-H, Li W, et al. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer. 2010;10:610.
18. Shen S, Gao J, Halicke HD, Huang X, Traganos F, Darzynkiewicz Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Radbosia rubescens, on tumor cells of different lineage. Int J Oncol. 2005;26:579-588.
19. Gao FH, Liu F, Wei W, et al. Oridonin induces apoptosis and senescence by increasing hydrogen peroxide and glutathione depletion in colorectal cancer cells. Int J Mol Med. 2012;29:649-655.
20. Shi M, Lu XI, Zhang J, et al. Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosis in gastric cancer cells through p53- and caspase-3-mediated mechanisms. Oncotargeter. 2016;7:22623-22631.
21. Li FF, Yi S, Wen L, et al. Oridonin induces NPM mutant protein translocation and apoptosis in NPM1c+ acute myeloid leukemia cells in vitro. Acta Pharmacol Sin. 2014;35:806-813.
22. Bi E, Liu D, Li Y, Mao X, Wang A, Wang J. Oridonin induces growth inhibition and apoptosis in human gastric carcinoma cells by enhancement of p53 expression and function. Braz J Med Biol Res. 2018;51:e7599.
23. Liu RX, Ma Y, Hu XL, et al. Anticancer effects of oridonin on colon cancer are mediated via BMP7/p38 MAPK/p53 signaling. Int J Oncol. 2018;53:2091-2101.
24. Wang S-Q, Wang C, Chang L-M, et al. Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/P13K/Akt pathway. Oncotargeter. 2016;7:72990-73002.
25. Ye YC, Wang HJ, Xu L, et al. Oridonin induces apoptosis and autophagy in murine fibrosarcoma L929 cells partly via NO-ERK-p53 positive-feedback loop signaling pathway. Acta Pharmacol Sin. 2012;33:1055-1061.
26. Gatsinzi T, Iverfeldt K. Sensitization to TRAIL-induced apoptosis in human neuroblastoma SK-N-AS cells by NF-kappaB inhibitors is dependent on reactive oxygen species (ROS). J Neuro-Oncol. 2011;104:459-472.
27. Liu SL, Liu Z, Zhang LD, et al. GSK3beta-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells. *Cell Cycle (Georgetown, Tex)*. 2017;16:2386-2395.

28. Lu J, Guo J-H, Tu X-L, et al. Tiron inhibits UVB-induced AP-1 binding sites transcriptional activation on MMP-1 and MMP-3 promoters by MAPK signaling pathway in human dermal fibroblasts. *PLoS ONE*. 2016;11:e0159998.

29. Leers MP, Hoop JG, van Beers M, van Rodijnen N, Pannebakker M, Nap M. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas. *Cytometry Part B: Clin Cytom*. 2005;64:43-52.

30. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. *Nat Rev Cancer*. 2014;14:359-370.

31. Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. *Cell Death Differ*. 2010;17:93-102.

32. Oliver TG, Meylan E, Chang GP, et al. Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. *Mol Cell*. 2011;43:57-71.

33. Saadatzadeh M, Elmi A, Pandya P, et al. The role of MDM2 in promoting genome stability versus instability. *Int J Mol Sci*. 2017;18:2216.

34. Pochampally R, Fodera B, Chen L, Shao W, Levine EA, Chen J. A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. *Oncogene*. 1998;17:2629-2636.

35. Erhardt P, Tomaselli KJ, Cooper GM. Identification of the MDM2 oncoprotein as a substrate for CPP32-like apoptotic proteases. *J Biol Chem*. 1997;272:15049-15052.

36. Chen L, Marechal V, Moreau J, Levine AJ, Chen J. Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. *J Biol Chem*. 1997;272:22966-22973.

37. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. *Nat Rev Cancer*. 2009;9:862-873.

38. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. *Nat Rev Cancer*. 2013;13:83-96.

39. Vasaturo M, Cotugno R, Fiengo L, et al. The anti-tumor diterpene oridonin is a direct inhibitor of Nucleolin in cancer cells. *Sci Rep*. 2018;8:16735.

40. Yan Y, Du Y, Wang G, Li K. Non-structural protein 1 of H3N2 influenza A virus induces nucleolar stress via interaction with nucleolin. *Sci Rep*. 2017;7:17761.

41. Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. *Cancer Cell*. 2009;16:369-377.

42. Pagliara V, Saide A, Mitidieri E, et al. 5-FU targets rpl3 to induce mitochondrial apoptosis via cystathionine-beta-synthase in colon cancer cells lacking p53. *Oncotarget*. 2016;7:50333-50348.

43. Russo A, Maiolino S, Pagliara V, et al. Enhancement of 5-FU sensitivity by the proapoptotic rpl3 gene in p53 null colon cancer cells through combined polymer nanoparticles. *Oncotarget*. 2016;7:79670-79687.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.